#NIH, #CDC, #FDA increased #SBIR/#STTR proposal budget limit.

  • May 24, 2019

Back in November of 2018, we noted that the SBIR/STTR Statute (15 U.S.C. §638) establishes a cap for the maximum dollar amount of SBIR and STTR awards, above which an agency must request an SBA-approved waiver, AND that as of 11/20/2018, agencies may issue a Phase I award (including modifications) up to $252,131 and a Phase II award (including modifications) up to $1,680,879 without seeking SBA approval.

Any award above those levels will require a waiver. Agencies considering this authority should review §7(i)(5) for additional information.

With the release of #NIH, #CDC, and #FDA solicitations (PA-19-272), (PA-19-270), (PA-19-273), and (PA-19-271) for SBIR/STTR funding the funding lines have adjusted their budgets accordingly.

Total funding support (direct costs, indirect costs, fee) normally may not exceed $252,131 for Phase I awards and $1,680,879 for Phase II awards.

In addition, #NIH has received a waiver from SBA, as authorized by statute, to exceed these total award amount hard caps for specific topics. The current list of approved topics can be found at https://sbir.nih.gov/funding#omni-sbir. Navigate to the “Program Descriptions and Research Topics” document, Appendix A or the “2019 SBA approved topics list for budget waivers”.

VIP: before adjusting your budget on your upcoming proposal, check with the participating SBIR funding agency to confirm budget adjustments.

Ready To Take the Next Step?

We assist our clients in locating, applying for, and evaluating the outcomes of non-dilutive grant funding. We believe non-dilutive funding is a crucial tool for mitigating investment risks, and we are dedicated to guiding our clients through the entire process—from identifying the most suitable opportunities to submitting and managing grant applications.